---
action_items:
- id: 9d5d2b7e4dd6
  severity: writing
  text: "Section 4.1 and 4.2 report single point estimates (e.g., 73.9%, 97.6%) for\
    \ success rates without any measure of uncertainty (SD, SE, or CI). While 24 trials\
    \ (SimplerEnv) and 50 rollouts (LIBERO) are mentioned, the variance across these\
    \ trials is not reported. Report mean \xB1 SD (or 95% CI) for all main results\
    \ to allow assessment of stability and effect magnitude."
- id: ee7dd49cc1fa
  severity: writing
  text: Tables 1-4 and Figure 1 present comparisons across multiple baselines and
    ablation settings (e.g., 12+ pairwise comparisons in Table 1 alone) without correcting
    for multiple comparisons. The claim of 'superiority' or 'significant' gains relies
    on uncorrected point estimates. Apply a correction (e.g., Bonferroni or Holm)
    for the family of comparisons or explicitly state that p-values are uncorrected
    and interpret 'significance' cautiously.
- id: 63b3248dd68e
  severity: writing
  text: Section 4.3 reports ablation results (e.g., 73.9% vs 57.3%) as fixed values.
    Since these are derived from the same experimental setup, the differences should
    be tested for statistical significance (e.g., paired t-test or bootstrap) rather
    than just compared as point estimates. Report the p-value or confidence interval
    for the difference to support the claim that the degradation is real and not due
    to random seed variance.
artifact_hash: 42bc6cf83e8ec23d1633a3d1459efcb214654e063ccd9a00df88a1940764a5ad
artifact_path: projects/PROJ-1027-dual-latent-memory-in-vision-language-ac/paper/metadata.json
backend: dartmouth
feedback: ''
github_authenticated: false
model_name: qwen.qwen3.5-122b
prompt_version: 1.1.0
reviewed_at: '2026-07-10T04:25:20.020039Z'
reviewer_kind: llm
reviewer_name: paper_reviewer_statistical_analysis
score: 0.0
verdict: minor_revision
---

The statistical reporting in this paper is currently insufficient to support the strength of the quantitative claims made. While the experimental protocols (number of trials/rollouts) are described in Sections 4.1 and 4.2, the results are presented exclusively as single point estimates (e.g., "73.9%", "97.6%") without any accompanying measure of uncertainty such as standard deviation (SD), standard error (SE), or confidence intervals (CI).

In robotic manipulation benchmarks like SimplerEnv and LIBERO, performance can vary significantly across random seeds or initial states. Reporting only the mean (or a single best run) obscures the stability of the method. For instance, a 16.6% gain over a baseline is impressive, but without the variance, a reader cannot determine if this gap is robust or if the distributions overlap significantly. The field standard for such benchmarks is to report mean ± SD over multiple seeds or trials.

Furthermore, the paper makes numerous comparative claims ("surpasses," "outperforms," "significantly better") across a large number of baselines and ablation settings (Tables 1, 2, 3, 4). These constitute multiple hypothesis tests. The current presentation treats each comparison as an isolated event, ignoring the multiplicity problem where the probability of at least one false positive increases with the number of comparisons. While formal p-values are not always required in ML, if the authors claim "superiority" based on these numbers, they must either provide statistical tests with appropriate corrections (e.g., Holm-Bonferroni) or temper their language to reflect that these are observed differences without statistical validation.

Finally, the ablation studies (Section 4.3) compare the full model against variants. These are paired comparisons (same seed, same task, different model). The current text simply lists the success rates. To rigorously support the claim that removing a component "causes degradation," a statistical test (e.g., paired t-test or Wilcoxon signed-rank test) should be performed on the per-trial data, and the resulting p-values or effect sizes should be reported.

The fix is primarily a reporting adjustment: re-analyze the existing trial data to compute and report SD/CI for all means, and perform the necessary statistical tests for the ablation and baseline comparisons. No new experiments are required, but the current numbers cannot be interpreted as definitive evidence of superiority without this context.
